Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

6089 - Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Shuhang Wang

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

S. Wang1, H. Chen2, J. Zhao1, J. Zhong1, J. Wang3

Author affiliations

  • 1 Thoracic Medical Oncology, Peking University Cancer Hospital, 100142 - beijing/CN
  • 2 Thoracic Medical Oncology, Peking University Cancer Hospital, 100100 - Beijing/CN
  • 3 Department Of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing/CN
More

Resources

Abstract 6089

Background

The utility of malignant pleural effusion (MPE) as a source of tissue for determining EGFRmutations to guide EGFR TKI therapy in advanced adenocarcinoma of the lung (LUAD) remains unclear. This study compared MPE, plasma and tumor as sources of tissue for EFGR mutational analysis in LUAD patients.

Methods

MPE samples were collected from 295 LUAD patients. Matched tissue and plasma samples were available for 92 patients, and 248 patients had plasma samples. EGFRexon 19-deletion and exon 21-L858R mutation were detected. The concordance of EGFR mutation status in MPE, tissue, and plasma were evaluated, and the predictive value of EGFRmutations in MPE with respect to efficacy of EGFR-TKI was investigated.

Results

The EGFRmutation rate in MPE samples was 39.3% (116/295). The concordance between MPEs and tissues was 87.1% (Kappa=0.712); the sensitivity and specificity of EGFRmutation in MPEs according to tissues was 71.4% and 96.5%,, respectively. 219 patients received EGFR-TKI, and the objective response rate of patients with EGFRmutations was similar for patients with EGFRmutation either in MPE, tissues or plasma (57.6 % vs 56.0 % vs 47.4%, p = 0.51). Similar results were found in progression free survival (8.9 months vs 9.0 months vs 7.7 months, p = 0.077 and overall survival (29.8 months vs 25.9 months vs 25.3 months, p = 0.33).

Conclusions

MPE is a reliable surrogate for tumor tissue for identifying EGFRmutations. MPE could offer reference of EGFRmutation to EGFR-TKIs treatment decision for advanced LUAD patients even when tissue and plasma were available.

Clinical trial identification

Legal entity responsible for the study

Peking University Cancer Hospital.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.